Format

Send to

Choose Destination
Semin Oncol. 2017 Oct;44(5):358-371. doi: 10.1053/j.seminoncol.2017.10.005. Epub 2017 Oct 10.

Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.

Author information

1
Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
2
Department of Urology, VU University Medical Center, Amsterdam, The Netherlands.
3
Department of Urology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: t.m.dereyke@amc.uva.nl.

Abstract

Treatment decisions are challenging in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel. The current review systematically searched the published literature on all treatment options, and assessed the risk of bias and quality of evidence. It found the best available evidence for effective prolongation of overall survival and progression-free survival for abiraterone acetate plus prednisone versus placebo plus prednisone and enzalutamide versus placebo. Other treatment modalities could be beneficial for individual patients by taking into consideration the: selection criteria of the randomized clinical trials, risk of bias, subgroup analyses, and quality of life and adverse events. Further research is needed to determine the sequence, timing asnd combination of different treatments.

KEYWORDS:

Castration-resistant; Chemotherapy; Prostatic neoplasms; Review; Survival; Treatment outcome

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center